


# Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020–June 30, 2022

## Appendix



**Appendix Figure.** Sensitivity analyses with estimates adjusted for test performance at 4 time periods over 130 days of convalescence using the formula observed prevalence + (specificity – 1) divided by sensitivity + (specificity – 1). Sensitivity estimates of IgG nucleocapsid assay at 4 time periods over convalescence were obtained from previous assay performance analyses (1,2). The manufacturer’s reported specificity of 99.6% (95% CI 99.1%–99.9%) was used for all adjustments. Adjusted 95% CI were obtained with parametric bootstrapping.

## References

1. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. *Sci Adv.* 2021;7:eabh3409. [PubMed <https://doi.org/10.1126/sciadv.abh3409>](https://doi.org/10.1126/sciadv.abh3409)

2. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, et al. Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications. *Emerg Infect Dis.* 2022;28:672–83. [PubMed](#)  
<https://doi.org/10.3201/eid2803.211885>